Effect of anti-herpes specific transfer factor

Area of Science:

• Immunology
• Virology
• Dermatology

Background:

• Recurrent herpetic infections pose a significant challenge due to limited effective treatments.
• Lymphocyte-derived therapies offer a potential avenue for managing viral infections.

Purpose of the Study:

• To evaluate the efficacy of a specific anti-herpes dialysate (AH-DLE) in patients with recurrent herpetic infections.
• To assess the impact of varying doses of AH-DLE on relapse rates and severity.

Main Methods:

• Lymphocytes were collected from convalescents of herpetic infections.
• Anti-herpes dialysate (AH-DLE) was prepared using standard lymphocyte processing.
• 37 patients received one, two, or three doses of AH-DLE at the onset of infection.

Main Results:

• 62.2% of patients showed marked improvement, with a significant decrease in herpes relapse frequency and/or duration.
• Mean annual relapses reduced from 12 to 3.5 post-therapy.
• No significant difference between one and two doses; three doses showed least favorable results, though 50% success in highly resistant cases.

Conclusions:

• AH-DLE therapy is effective in reducing the frequency and duration of recurrent herpetic infections.
• The treatment demonstrates promise, particularly for patients resistant to conventional therapies.
• Further research into optimal dosing strategies for AH-DLE may be warranted.